Lotus Pharmaceutical Co., Ltd. (1795)
TWSE
195.50
+1.50 (+0.77%)
Closed
Aug 26, 2026
Day's Range
193.00198.50
52 wk Range
170.50369.50
Financial Statements - 1795 - Lotus Pharmaceutical Co., Ltd.
Revenue
20.50B▲ 10.4%
Net Income
4.72B▼ 6.8%Net Margin 23.0%
EBITDA
8.14B▼ 0.9%
Free Cash Flow
3.12B▼ 33.3%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 20.50B | 18.58B | 16.95B | 14.63B | 12.64B | 10.72B |
| Cost of Goods | 8.60B | 7.66B | 7.57B | 6.82B | 7B | 6.13B |
| Gross Profit | 11.90B | 10.92B | 9.38B | 7.80B | 5.64B | 4.59B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 5.89B | 6.01B | 4.89B | 4.10B | 2.32B | 1.61B |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | - | - | - | - | - | - |
| Pre Tax Income | 5.71B | 6.35B | 5.10B | 3.94B | 1.87B | 1.30B |
| Income Tax | 998.12M | 1.29B | 997.29M | 919.45M | 466.64M | 274.58M |
| Net Income | 4.72B | 5.06B | 4.10B | 3.02B | 1.40B | 1.02B |
| EPS Basic | 18.14 | 19.35 | 15.72 | 11.59 | 5.5 | 4.22 |
| EPS Diluted | 18.04 | 19.23 | 15.67 | 11.54 | 5.47 | 4.22 |
| Basic Shares Outstanding | 260.26M | 261.85M | 261.17M | 260.63M | 255.17M | 243.11M |
| Diluted Shares Outstanding | 260.26M | 261.85M | 261.17M | 260.63M | 255.17M | 243.11M |
| Ebit | 6.61B | 6.93B | 5.66B | 4.32B | 2.16B | 1.63B |
| Ebitda | 8.14B | 8.21B | 6.86B | 5.25B | 2.96B | 2.34B |
| Net Income Continuous Operations | 5.71B | 6.35B | 5.10B | 3.94B | 1.87B | 1.30B |
| Minority Interests | - | - | - | - | 0 | -2.85M |
| Preferred Stock Dividends | 0 | 0 | 0 | 0 | 0 | 0 |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
